Finanzen von Sana Biotechnology Inc (SANA)SANASana Biotechnology Inc

Evaluating the bottom line, Sana Biotechnology, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -152.87%, provide a clear picture of how effectively SANA converts its operational activities into shareholder value.

In the context of the broader market, SANA competes directly with industry leaders such as IAM and GERN. With a market capitalization of $709.48M, it holds a significant position in the sector. When comparing efficiency, SANA's gross margin of N/A stands against IAM's N/A and GERN's 94.94%. Such benchmarking helps identify whether Sana Biotechnology, Inc. is trading at a premium or discount relative to its financial performance.

Sana has reported consistent net losses, with the latest quarterly net income showing a loss of $63.6 million in Q2 2026. The company has a current ratio of 1.38, indicating it can cover its short-term liabilities, but the overall financial health is concerning due to negative earnings and equity trends.